novo oral semaglutide Here's Nordisk's First Obesity Drug In Europe With Proven Heart Health Impact Details of failed studies cast

Amy Hudson and Dr

Eli Lillys oral GLP-1 candidate orforglipron met all primary and secondary endpoints in a Phase 3 study of adults with type 2 diabetes, the

There is substantial evidence suggesting that AMPK is dysregulated in animals and humans with metabolic syndrome or T2D, and that AMPK activation (physiological or pharmacological) can improve insulin sensitivity and metabolic health

CVS Health will reinstate coverage of Eli Lilly's weight-loss injectable Zepbound and begin coverage of the anti-obesity pill Foundayo.

Farxiga (Dapagliflozin) is a medication used to treat type 2 diabetes and more

GLP-1 therapies may help reduce antipsychotic-associated weight gain and metabolic risk in patients with serious mental illness.